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Abstract 
Neuroimaging is continuously advancing at
a rapid rate and has progressed from excluding
relatively  uncommon  secondary  causes
(stroke, tumor) to assisting with early diagno-
sis and subtype of dementia. Structural imag-
ing has given way to functional, metabolic and
receptor imaging. 
Introduction
Neuroimaging is continuously advancing at
a rapid rate and has progressed from excluding
relatively  uncommon  secondary  causes
(stroke, tumor) to assisting with early diagno-
sis and subtype of dementia. Structural imag-
ing has given way to functional, metabolic and
receptor  imaging.  An  emerging  focus  is  the
appreciation  of  human  connectomics,  net-
work-opathies and their imaging counterparts.
18Fluorodeoxyglucoe positron emission tomog-
raphy (18FDG-PET) brain, single photon emis-
sion  computed  tomography  (SPECT)  brain,
PET Pittsburgh Compound B (PIB) and PET
receptor (Dopa) imaging are becoming more
widespread and gaining acceptance as part of
the  routine  work  up  (Table  1).  18FDG-  PET
brain in particular has been an important tool
in assisting in the early diagnosis of mild cog-
nitive impairment (MCI) type of case as well
as in differentiating different types of demen-
tia, with frontotemporal disorders (FTD) and
Alzheimer’s  disease  (AD)  already  being  an
Food and Drug Administration asserted indica-
tion for example.1 Furthermore, basic neuro-
science  is  increasingly  delineating  newer
molecular  phenotypes  (beta  amyloid,  alpha
synuclein  and  TDP-43)  and  subcategories
which are particularly complex with FTD (TDP
43, tau, FUS, C90RF2). The pathologies take
effect at the synaptic and neuronal level and
are the earliest events in these disease states.
Neuroimaging is increasingly able to decipher
these earlier changes long before the clinical
state even emerges or the extensive atrophy
seen on structural scans. As late or end stages
are  barely  amenable  to  significant  interven-
tion, the earlier detection is key.
Currently  PET    brain  imaging  offers  the
most  accurate  diagnostic  method  for  the  5
main dementia categories as well as  a number
of the subcategories2 (Table 2). A number of
patterns have emerged that reliably differenti-
ate  the  major  dementia  subtypes.  This  is
important for treatment and prognostic deci-
sion making. For example the posterior corti-
cal atrophy syndrome (Benson syndrome), an
AD variant progresses very slowly with largely
retained cognitive function, at the same time
dominated  by  complex  visual  impairments
including  visual  agnosias  and  Balint’s  syn-
drome (Figure 1).3 With FTD (frontotemporal
hypoemtabolism) (Figure 2) and AD (tempo-
ral, parietal, posterior cingulate) the footprint
of hypotemetabolism is relatively easily identi-
fied (Figure 3). However with Parkinson’s dis-
ease with dementia (PDD) and Diffuse Lewy
Body Disease (DLBD), the differentiating fea-
tures even on PET scanning are less distinct
and considerable overlap in the patterns are
seen and consequently confusion may arise.
This is particularly the case with PDD, DLDB
and cortical basal ganglionic (CBG) disease.
PDD and DLBD are particularly challenging as
there is no clear PET pattern as for example
with AD and FTD. This is perhaps not surpris-
ing as DLDB and AD share features at a clini-
cal, neuroimaging, pathological and pharma-
cotherapeutic level.4 Futhermore, Parkinson’s
disease (PD), PDD, DLBD and AD represent a
pathological spectrum with loss of both cholin-
ergic neurons and dopaminergic neurons as
the most prominent neurotransmitter pertur-
bation  initially.5 Adding  to  the  complexity,
there is overlap with AD and cognitive vascular
disorders  (CVD),  the  frontal  variant  of
Alzheimer’s and the frontal variant of FTD that
present added diagnostic challenges in indi-
vidual cases. Even more importantly, diagnosis
and differentiation may not be possible by clin-
ical means alone especially in the pre-sympto-
matic  phase  when  no  cognitive  impairment
exists particularly in the context of presumed
high cognitive reserve. However intervention
and treatment may yield the most significant
results at this stage.6
In addition to the 4 most common dementia
syndromes discussed, newer dementia etiolo-
gies continuously added and expand the diag-
nostic work up. Autoimmune dementias and
the  prefrontal  atrophy  secondary  to  chronic
stimulation of the pain matrix (chronic pain
syndrome) is also regarded as a neurodegener-
ative  condition  today.  Brain  atrophy  and  as
such neurodegeneration has been associated
with various chronic pain conditions including
fibromyalgia,  posttraumatic  headache,  com-
plex  regional  pain  syndrome  (CRPS),  and
chronic back pain.7-10 The potential cause and
effect  relationship  of  the  atrophy  with  pain
continues  to  be  elucidated.  In  relation  to
dementias, memory and pain processing share
close anatomic relationships. Numerous func-
tional  neuroimaging  studies  using  positron
emission tomography (PET)11-13 and function-
al  magnetic  resonance  imaging  (fMRI)14,15
have demonstrated that the anterior cingulate
cortex  (ACC)  and  posterior  cingulate  cortex
(PCC) have key roles in processing of pain per-
ception.16 Lesional studies have corroborated
these  findings.17,18 The  ACC  has  not  been
demonstrated to be involved in coding stimu-
lus  intensity  or  location  but  participates  in
both the affective and attentional components
of  pain  sensation  and  response.  Increased
blood flow is also found in the posterior pari-
etal and prefrontal cortices and is thought to
reflect  networks  for  attention  and  memory
activated by painful stimulation. Memory and
pain processing networks are physically close
in  the  cingulate  cortex.  Episodic  memory
retrieval is predominately in the caudal portion
of the PCC while pain processing occurs in the
rostral  portion  of  the  PCC.19 Given  that
patients  with  Alzheimer’s  disease  and  other
neurodegenerative  dementias  are  noted  to
report  less  pain  and  may  receive  less  anal-
gesics that comparable normal peers, consid-
eration has been provoked that the dementia
related  neurodegeneration  process  may  be
affecting pain processing pathways.  However,
studies have demonstrated heightened magni-
tude and duration of activity in the ACC and
other pain processing areas during pain stim-
uli in Alzheimer’s disease patients.20 As such
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[page 26] [Neurology International 2012; 4:e7]the  perception  of  pain  is  not  diminished  in
Alzheimer’s,  and  should  raise  awareness  of
clinical care providers to insure adequate anal-
gesia for dementia patients with painful condi-
tions.   
PET brain scan imaging and cerebrospinal
fluid (CSF) biomarkers are becoming increas-
ingly  important  to  diagnose  dementia  syn-
dromes especially in the setting of overlap syn-
dromes.21,22 Learning  to  identify  metabolic
uptake  patterns  by  cartographic  analysis  as
well as semi-quantitative methods may be cru-
cial for correct diagnosis in the face of conflict-
ing clinical as well as neuro-radiological find-
ings. The four major neurodegenerative dis-
eases  include  AD,  DLBD,  FTD  and  CVD  in
approximate order of frequency. AD and FTD
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Table 1. Spectrum of current functional imaging modalities.
Magnetic resonance imaging multimodaiity
Magnetic resonance imaging (routine series)
T1/T2 fluid attenuated inversion recovery, gradient echo sequence, magnetic resonance angiogram 
largely to detect degree of concomitant vascular disease, atrophy pattern and other secondary 
pathologies
Magnetic resonance imaging - diffusion tensor imaging
Fiber tract pathology especially in traumatic brain injury, multiple sclerosis
Magnetic resonance imaging - quantitative atrophy estimation
At least 5 different patterns of the major dementia syndromes (Seeley WW et al.)22
Magnetic resonance imaging - perfusion
Perfusion as a reflection of hypometabolism, similar to single photon emission computed 
tomography (perfusion) and positron emission tomography (metabolism) patterns of abnormality
Magnetic resonance spectroscopy
Biochemical analysis, choline, lactate particularly useful in brain tumor diagnosis
Single photon emission computed tomography
Hypoperfusion (in vascular or hypometabolism)
Hyperperfusion for example with ictal foci
Position emission tomography brain
Frontotemporal disorders 
Alzheimer’s disease 
Diffuse lewy body disease 
Parkinson’s
Progressive supranuclear palsy
Huntington’s
Cortical basal ganglionic cognitive vascular disorders
Intrinsic state connectivity maps
Default mode
Salience network
Parkinson’s (increased connectivity of the basal ganglionic and thalamocortical loops)
Cortical basal ganglionic 
Cognitive vascular disorders ?
Quantitative electroencephalographic and magnetoencephalographic
Alzheimer’s disease - reduced connectivity of alpha and beta in frontotemporal and frontoparietal
regions
Frontotemporal disorders - uncertain
Parkinson’s - increased connectivity of alpha and beta locally and globally
Diffuse lewy body disease - reduced connectivity alpha range locally and globally
Figure 1. 18FDGPET brain: posterior cortical atrophy syndrome with marked posterior
cortical hypometabolism.
Figure  2.  FTD  end  stage  with  extensive
bifrontal  cortical  atrophy  (top)  and
18FDGPET brain of early non fluent apha-
sia  subtype  (down),  demonstrating  left
inferior  frontal  hypometabolism  (arrow)
in context of normal structural MRI scan.(Figure 2) have distinct and easily identifiable
patterns and CVD is guided primarily by stroke
related imaging. The situation with DLBD can
be difficult due to the overlap of neuropatholo-
gies. A correct diagnosis is nevertheless vital
to guide care for the patient. Refining the diag-
nosis may assist with appropriate treatment
and in avoiding serious side effects not the
least of which include neuroleptic sensitivity
such  as  neuroleptic  malignant  syndrome  or
catatonia. People with DLDB generally respond
better  to  acetylcholinergic  (Ach)  therapy  in
terms of improved alertness, less fluctuation in
cognition  and  memory  than  do  people  with
AD.4 The complex clinical and neuroradiologi-
cal  patterns  of  the  dementia  syndromes  no
doubt foster misdiagnosis. The neuroradiolog-
ical findings of DLDB may be initially confused
the diagnosis of AD diagnosis. Hallucinations,
a hallmark of DLDB can occur with AD as well
as other dementias. A recent report of a specif-
ic 5HT - 2A antagonist specific for visual hallu-
cinations with DLDB is further reason for pre-
cise diagnostic accuracy translating into ther-
apeutic effectiveness.23 There are already sev-
eral  recognized  metabolic  features  of  PET
scanning that have been identified with DLDB,
namely i) diffuse glucose hypometabolism in
entire cortex including the occipital region typ-
ical feature of DLBD and distinctive from AD,
ii) lateral occipital hypometabolism (Figure 3)
which may have the highest sensitivity and iii)
posterior  cingulate  preserved  metabolism  or
posterior cingulate island sign, (PCIS) which
may have the highest specificity24-26 (Figure
4).  However,  the  so  called  PCIS  appears  to
reflect  the  much  more  pronounced  occipital
hypometabolism relative to the also reduced
(but to a lesser extent) or sometimes normal
metabolism of the posterior cingulate cortex.22
With AD on the other hand, hypometabolism
is seen very early in the medial portions of the
parietal lobes as well as the posterior cingulate
region. The difficulty posed by the fluctuating
symptomatology adds to the diagnostic dilem-
ma. In addition, the uncertainty of hallucina-
tion  origin,  whether  drug  induced,  due  to
DLBD or AD is a frequent frustration shared by
both  patients  and  physicians  treating  these
conditions. The advent of biomarker assisted
diagnosis has already initiated new diagnostic
criteria for AD that enable a pre-mortem diag-
nosis that is heavily reliant on positive CSF
and PET findings.27 The trend of clinical, PET
and  CSF  diagnostic  features  rendering
increased diagnostic accuracy will likely trans-
late similarly in the DLDB-Parkinsonism com-
plex as it has already done for example with
MCI and AD.28With the advent of MR perfusion
scanning  giving  similar  information  to  PET
brain  scanning,  this  modality  may  become
more desirable in view of its availability and
lack of radiation.29 A continuously expanding
therapeutic armamentarium for DLDB both in
terms of receptors23 for symptom alleviation as
well as disease modifying therapies30 all bode
for precise diagnostic accuracy. 
Emerging imaging modalities:
default mode network or intrinsic
connectivity networks imaging and
other (molecular) networks
The Default Mode Network (DMN) can be
imaged by functional MRI (resting state with-
out  activation  procedures)  and  reflects  the
basal or default mode activity of the brain. It
links particular brain regions that includes the
posterior  cingulate,  the  precuneus,  lateral
parietal, lateral temporal, medial frontal areas.
DMN impaired connectivity has already been
shown  in  AD,  FTD,  schizophrenia,  epilepsy,
autism  later  life  depression.31 The  DMN  is
active during rest and becomes less active dur-
ing cerebral task engagement. It is implicated
in the pathophysiology of AD as the distribu-
tion of the DMN is similar to the fibrillar amy-
loid deposition in patients with AD (amyloid
PET scanning).32 The A-beta deposition over-
laps considerably with the DMN and the tau
deposition overlaps with the DMN component
that is concerned with episodic memory.33 It
has been surmised that over-activity of DMN
(posterior  cingulate,  later  parietal,  medial
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[page 28] [Neurology International 2012; 4:e7]
Table 2. Positron emission tomography brain patterns in dementias.
Dementia subtype 18Fluorodeoxyglucoe positron emission 
tomography hypometabolism pattern
Alzheimer Relatively symmetric parietotemporal, medial 
temporal, posterior cingulate, frontal association cortex 
to lesser degree
Alzheimer’s disease variant  Occipital hypometabolism predominates
(Posterior cortical atrophy syndrome)
Frontotemporal disorders  Frontal and anterior temporal hypometabolism
behavioral variant
Parkinson’s disease with dementia Temporo-parietal, may be similar to AD
Diffuse lewy body disease  Occipital and temporal hypometabolism
Cognitive vascular disorders Cortical and subcortical, singular or 
multifocal, correlating with structural imaging abnormality
Corticobasal degeneration Global reduction in metabolism as well 
as asymmetric prefrontal, premotor, 
pensorimotor superior temporal, parietal hypometabolism 
with thalamic hypometabolism contralateral to limb apraxia
Huntington’s Caudate nucleus hypometabolism, frontal 
association cortex to a lesser degree
Progressive supranuclear palsy Caudate nucleus, putamen, thalamus, pons, superior and 
anterior frontal cortex
Note that FDG PET increases diagnostic accuracy beyond that derived from clinical evaluation.1
Figure  3.  Transaxial  18FDGPET  brain
revealing bilateral predominantly occipital
hypometabolism (arrows) in a patient with
DLBD.
Figure 4. Sagittal 18FDGPET brain reveal-
ing  preserved  mid  to  posterior  cingulate
metabolism (arrows) with temporoparietal
hypometabolism.frontal) in younger life may lead to a metabol-
ic impairment predisposing people to amyloid
deposition in later life.34
The DMN is known to subserve several key
memory processes including episodic encod-
ing, retrieval, autobiographical, metamemory
processes, moral decision making and theory
of mind. Petrella et al. reported lower connec-
tivity in DMN in patients with MCI who subse-
quently  were  diagnosed  with  AD  over  a  2-3
years period.32 This type of functional connec-
tivity  MRI  (fc-MRI),  is  an  attractive  tool
because MRI scanners with blood oxygen level
dependent (BOLD) capability are widely avail-
able and fc-MRI is non invasive, radiation free,
can be repeated multiple times and have short
acquisition time of 5-8 min.35
The quest for neuroimaging biomarkers for
diagnosing pre-clinical disease may soon be
realized albeit with perhaps a complementary
role played by FDG-PET, Pittsburgh compound
B PET (PiB PET), PET neurotransmitter imag-
ing and fc-MRI of the DMN and perhaps other
networks such as the salience (for FTD) and
attentional  networks.36-39 With  intrinsic  con-
nectivity networks the pattern for AD and FTD
is fairly clear. However for the PDD and DLDB
the pattern is less obvious and there may also
be hyperactivity in the BG as opposed to the
usual underactivity seen in the other neurode-
generative conditions (Table 3).
Neurotransmitter and neuro-
transmtter receptor position emis-
sion tomography (and sometimes
single photon emission computed
tomography) imaging
In the hopes of guiding therapy more accu-
rately,  the  cholinergic  (nicotinic  receptors)
and dopaminergic systems have been investi-
gated in this regard. An increase in 11C nico-
tinic binding sites as well as associated cogni-
tive  improvement  were  reported  after  3
months of rivastigmine for AD patients.36 At
times  neurodegenerative  conditions  coexist
and unraveling the most pertinent neurotrans-
mitter systems at fault is useful. This has been
shown  for  acetylcholine  involvement  in
Parkinsons with and without dementia by 11C
methyl - 4- piperidyl acetate (MP4A). In this
study, the dopaminergic system was also meas-
ured  using  18F  fluorodopa  (FDOPA)  which
revealed decreased uptake in the striatum and
MP4A was decreased in the Parkinson’s group
with dementia.37
Cortical atrophy patterns
Cortical atrophy patterns are generally dis-
cernible at a later stage of the process and per-
haps  the  least  sensitive  (Table  4).
Nevertheless, a recent pivotal study showed 5
different  neurodegenerative  syndromes  and
their atrophy patterns corresponding to 5 dif-
ferent  intrinsic  functional  connectivity  net-
works.39 In particular the salience network has
been shown to correlate with frontotemporal
lobe dementia.40 This relatively novel approach
of brain analysis, called connectomics by some
is showing promising results. Assessment of
brain connectonomics is regarded as an area
of priority in future cognitive research (The
Human Connectome Project).41
The importance of considering cog-
nitive reserve status by functional
imaging in conjunction with cogni-
tive or neuropsychological testing
No  direct  relationship  exists  between  the
extent of pathology and clinical  manifestation
of the underlying disease or damage for that
matter.
Katzman et al., reported on 10 elderly nor-
mal women with advanced AD pathology sup-
ported  this  premise,  speculating  that  their
brains had more cognitive reserve.42 Cognitive
reserve  is  considered  to  include:  i)  brain
reserve capacity (correlate - hardware, brain
size, neural count or synapse count; ii) cogni-
tive reserve (correlate - software). Attempting
to  cope  with  brain  damage  using  cognitive
compensatory  approaches.  Higher  education,
bilingualism, literacy and participation in hob-
bies  for  example,  allow  people  to  withstand
brain damage better. 
Cognitive reserve in turn has been divided
into: i) Neural reserve: cerebral networks less
susceptible to disruption due to greater inher-
ent efficiency; ii) neural compensation: post
brain damage, additional or nonconventional
networks are deployed to compensate for brain
damage.43
Functional imaging studies support the neu-
ral reserve and neural compensation reflecting
individual compensatory differences to pathol-
ogy. For example, two people with the same
cognitive impairment may have markedly dif-
ferent  degrees  of  underlying  AD  pathology.
This is clearly important for the diagnosis of
preclinical Alzheimer’s disease, as mild cogni-
tive impairment (MCI) patients may have both
minimal pathology or more extensive patholo-
gy. The cognitive reserve (CR) hypothesis, is
used to describe this variability and is consid-
ered  an  important  part  of  the  assessment
therefore. Clinical evaluation alone cannot be
relied on and biomarkers (whether CSF analy-
sis of tau and amyloid beta 1-42 or metabolic
imaging) will be part of the work up.44
Since  the  proposal  of  the  CR  hypothesis,
this has been recently supported using the PIB
and 18FDG PET in relation to education in mild
AD. In this study, 12 high educated (15 or more
years) and 13 low educated patient with the
same degree of cognitive deterioration were
evaluated with PET brain scanning using both
[11C] PIB and  18F-Fluorodeoxyglucose as lig-
ands.  The  high-educated  people  showed
increased PIB uptake in the lateral frontal cor-
tex as well as lower glucose metabolic rate in
the temporoparietal cortical regions compared
to low educated people.
How may we utilize the various
imaging modalities today and in the
near future?
A likely hierarchical approach to using sur-
rogate neuroimaging in cognitive patients may
be as follows may take the following format: i)
Resting  State  Network  Imaging  (DMN,
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Table 4. Atrophy patterns in dementia subtypes.
Dementia subtype Atrophy pattern
Alzheimer Temporoparietal, medial hippocampus, precuneus
Frontotemporal disorders behavioral variant Frontotemporal
Parkinson’s with dementia Temporoparietal
Diffuse lewy body disease  Parietal atrophy but no hippocampal atrophy. 
Caudate atrophy currently debatable
Vascular cognitive disorder (vascular cognitive  Nil specific, subcortical leukoaraiosis as
impairment, vascular dementia) opposed to periventricular rimming 
leukoaraiosis is frequent 
Progressive supranuclear palsy Midbrain atrophy (Hummingbird, Penguin signs)
Cortical basal ganglionic   Pronounced fronto-parietal atrophy, often 
asymmetric, corpus callosum atrophy
Table 3. Intrinsic connectivity network patterns in dementias.
Dementia subtype Intrinsic connectivity pattern
Alzheimer Default mode network shows reduced connectivity
Frontotemporal lobe disorder behavioral variant Salience network shows reduced connectivity
Parkinson’s Basal Nuclei-thalamocortical loops show increased 
connectivity
Diffuse lewy body disease  Uncertain at present but may show ascending 
brainstem projection system
Cortical basal ganglionic   UncertainSalience and others) by f-MRI; ii) beta amyloid
accumulation assessed by PET brain PIB (also
CSF assays); iii) the subsequent synaptic dys-
function assessed by FDG-PET brain; iv) final-
ly, neuronal loss follows, as assessed by volu-
metric MRI.
Conclusion
Since the revised AD criteria now include
biomarker testing, neuroimaging (particularly
PET)  has  gained  acceptance.  However,  the
conditions  with  most  ambiguous  results  on
PET scanning (PDD and DLDB), certain neu-
roradiological identification such as the PCIS
may be an important feature in improving con-
fidence in the discrimination between AD and
DLBD in clinical overlap syndromes and sup-
port differing therapeutics. For all the other
conditions, PET reliably discerns the differing
syndromes. The advent of ICN imaging looks
promising to enable an even earlier and more
precise diagnosis of the ever expanding array
of dementia syndromes.
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